Home > Insider Trading > Filing (0001209191-15-042801)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1267565	Collegium Pharmaceutical Inc	COLL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1253886	G Patrick Enright	800 El Camino Real Suite 220 Menlo Park CA 94024	No	No	Yes	No
1419701	L.p. Partners Venture Longitude	800 El Camino Real Suite 220 Menlo Park CA 94024	No	No	Yes	No
1430719	Longitude Capital Associates, L.p.	800 El Camino Real Suite 220 Menlo Park CA 94024	No	No	Yes	No
1430720	Longitude Capital Partners, Llc	800 El Camino Real Suite 220 Menlo Park CA 94024	No	No	Yes	No
1431159	Juliet Bakker Tammenoms	800 El Camino Real Suite 220 Menlo Park CA 94024	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-05-12	3,060,502	$0.00	3,060,502	No	4	C	Indirect	By Longitude Venture Partners, L.P.
Common Stock	Acquisiton	2015-05-12	196,070	$12.00	3,256,572	No	4	P	Indirect	By Longitude Venture Partners, L.P.
Common Stock	Acquisiton	2015-05-12	61,340	$0.00	61,340	No	4	C	Indirect	By Longitude Capital Associates, L.P.
Common Stock	Acquisiton	2015-05-12	3,930	$12.00	65,270	No	4	P	Indirect	By Longitude Capital Associates, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Longitude Venture Partners, L.P.
No	4	P	Indirect	By Longitude Venture Partners, L.P.
No	4	C	Indirect	By Longitude Capital Associates, L.P.
No	4	P	Indirect	By Longitude Capital Associates, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2015-05-12	12,837,935	$0.00	1,860,570	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2015-05-12	257,303	$0.00	37,290	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2015-05-12	3,160,905	$0.00	458,102	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2015-05-12	63,356	$0.00	9,182	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2015-05-12	5,045,381	$0.00	741,830	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2015-05-12	101,128	$0.00	14,868	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

All series of convertible preferred stock automatically converted into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis immediately prior to the closing of the initial public offering and had no expiration date.
Reflects the conversion of preferred stock into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis which became effective on May 12, 2015, and includes 10,616 shares issued on May 12, 2015 to LVP, and 212 shares issued on May 12, 2015 to LCA, upon conversion of the Series D Convertible Preferred Stock in payment of accrued dividends thereon.
This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP, as general partner of each of LVP and LCA, has the power to vote and dispose of securities held by each of them and may be deemed to have beneficial ownership of the shares owned by LVP and LCA. Enright and Bakker are each managing members of LCP and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by the reporting persons. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein.